Biodesix Inc(BDSX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.17 | Insider Own | 42.13% | Shs Outstand | 10.6M | Perf Week | -4.12% |
| Market Cap | 0.27B | Forward P/E | - | EPS next Y | 37.58% | Insider Trans | 0.97% | Shs Float | 6.1M | Perf Month | 7.12% |
| Enterprise Value | 0.32B | PEG | - | EPS next Q | -0.75 | Inst Own | 41.41% | Short Float | 2.46% | Perf Quarter | 73.48% |
| Income | -0.03B | P/S | 2.67 | EPS this Y | 42.77% | Inst Trans | 6.47% | Short Ratio | 1.51 | Perf Half Y | 36.55% |
| Sales | 0.10B | P/B | 30.04 | EPS next 5Y | 39.91% | ROA | -30.33% | Short Interest | 0.15M | Perf YTD | 282.94% |
| Book/sh | 0.87 | P/C | 9.13 | EPS past 3/5Y | 46.84% 27.68% | ROE | -540.01% | 52W High | -16.83% ($31.31) | Perf Year | 149.62% |
| Cash/sh | 2.85 | P/FCF | - | Sales past 3/5Y | 32.31% 14.2% | ROIC | -35% | 52W Low | 395.06% ($5.26) | Perf 3Y | -10.21% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 43.48% | Gross Margin | 82.5% | Volatility(W/M) | 7.23% 9.1% | Perf 5Y | -86.52% |
| Dividend TTM | - | EV/Sales | 3.07 | Sales Y/Y TTM | 34.46% | Oper. Margin | -19.99% | ATR (14) | 2.09 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.77 | EPS Q/Q | 54.83% | Profit Margin | -26.97% | RSI (14) | 52.56 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.85 | Sales Q/Q | 34.18% | SMA20 | 0.17% ($26) | Beta | 0.56 | Target Price | $34 |
| Payout | - | Debt/Eq | 7.86 | Earnings | 2026/8/5 | SMA50 | 10.77% ($23.51) | Rel Volume | 0.54 | Prev Close | $27.08 |
| Employees | 334 | LT Debt/Eq | 7.68 | EPS/Sales Surpr. | 21.27% 3.21% | SMA200 | 70.59% ($15.26) | Avg Volume(3M) | 0.10M | Price | $26.04 |
| IPO | 2020/10/28 | Option/Short | No/Yes | Trades | 947 | Volume | 53,488 | Change | -3.84% |
Company
BDSX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🫁 A US-based molecular diagnostics company specializing in tests for lung disease diagnosis. It operates a portfolio of blood-based diagnostic tests designed to help with the early detection of lung nodules and lung cancer, and also provides biomarker analysis services for pharmaceutical companies. It is classified as a precision diagnostics specialist focused on the lung health segment.
Over the past 1 year, on the higher side
17% below its 1-year high.
BDSX has weak earning power
Review management risk carefully before investing
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +42.8% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -10.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 41.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
VTI 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $275M.
BDSX $275M PER -
TMO $223B PER 32.5
DHR $141B PER 35.6
NTRA $47B PER -
FAQ
What kind of company is BDSX?
BDSX belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of BDSX?
The market cap of BDSX is approximately $275M, ranking 3,829 within its sector.
What is the 52-week high and low for BDSX?
BDSX has recorded a 52-week high of $31.31 and a low of $5.26.
